{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T13:40:25Z","timestamp":1788961225926,"version":"build-2803163510"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To identify patient- and disease-related characteristics that make it possible to predict higher disease severity in recent-onset PsA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed a multicenter observational prospective study (2-year follow-up, regular annual visits). The study population comprised patients aged \u2265 18 years who fulfilled the CASPAR criteria and less than 2 years since the onset of symptoms. Severe disease was defined at each visit as fulfillment of at least 1 of the following criteria: need for systemic treatment, Health Assessment Questionnaire (HAQ) &amp;gt; 0.5, polyarthritis. The dataset contained data for the independent variables from the baseline visit and follow-up visit number 1. These were matched with the outcome measures from follow-up visits 1 and 2, respectively. We trained a logistic regression model and random forest\u2013type and XGBoost machine learning algorithms to analyze the association between the outcome measure and the variables selected in the bivariate analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The sample comprised 158 patients. At the first follow-up visit, 78.2% of the patients who attended the clinic had severe disease. This percentage decreased to 76.4% at the second visit. The variables predicting severe disease were patient global pain, treatment with synthetic DMARDs, clinical form at diagnosis, high CRP, arterial hypertension, and psoriasis affecting the gluteal cleft and\/or perianal area. The mean values of the measures of validity of the machine learning algorithms were all \u2265 80%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our prediction model of severe disease advocates rigorous control of pain and inflammation, also addressing cardiometabolic comorbidities, in addition to actively searching for hidden psoriasis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2022.891863","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T16:53:59Z","timestamp":1651164839000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Severe Disease in Patients With Recent-Onset Psoriatic Arthritis. Prediction Model Based on Machine Learning"],"prefix":"10.3389","volume":"9","author":[{"given":"Rub\u00e9n","family":"Queiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Seoane-Mato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Laiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Galindez Agirregoikoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Montilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Sang","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A.","family":"Pinto Tasende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jos\u00e9","family":"Bethencourt Baute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Joven Ib\u00e1\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elide","family":"Toniolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Pruenza Garc\u00eda-Hinojosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,28]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis.","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.semarthrit.2020.04.001","article-title":"Mortality in psoriatic arthritis: Risk, causes of death, predictors for death.","volume":"50","author":"Elalouf","year":"2020","journal-title":"Semin Arthritis Rheum."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19010058","article-title":"Cardiometabolic comorbidities in psoriasis and psoriatic arthritis.","volume":"19","author":"Puig","year":"2017","journal-title":"Int J Mol Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.reuma.2018.09.008","article-title":"Spanish registry of recent-onset psoriatic arthritis (REAPSER study): aims and methodology.","volume":"15","author":"Queiro","year":"2019","journal-title":"Reumatol Clin (Engl Ed)."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study.","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum."},{"key":"B6","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/s0025-7753(01)72224-5","article-title":"The ISCA (systematic interview of alcohol consumption), a new instrument to detect risky drinking.","volume":"117","author":"Gual","year":"2001","journal-title":"Med Clin (Barc)."},{"key":"B8","year":"2021","journal-title":"The IPAQ Group Guidelines for Data Processing and Analysis of the International Physical Activity Questionnaire (IPAQ)\u2014Short and Long Forms."},{"key":"B9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1136\/ard.62.2.127","article-title":"Assessment of enthesitis in ankylosing spondylitis.","volume":"62","author":"Heuft-Dorenbosch","year":"2003","journal-title":"Ann Rheum Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"ii65","DOI":"10.1136\/ard.2004.031237","article-title":"Psoriasis assessment tools in clinical trials.","volume":"64","author":"Feldman","year":"2005","journal-title":"Ann Rheum Dis."},{"key":"B11","first-page":"2116","article-title":"Spanish version of the health assessment questionnaire: reliability, validity and transcultural equivalency. Grupo para la adaptacion del HAQ a la Poblacion Espanola.","volume":"20","author":"Esteve-Vives","year":"1993","journal-title":"J Rheumatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1136\/annrheumdis-2014-205207","article-title":"A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the psoriatic arthritis impact of disease (PsAID) questionnaire, a 13-country EULAR initiative.","volume":"73","author":"Gossec","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1002\/1529-0131(199812)41:12<2263::AID-ART23>3.0.CO;2-I","article-title":"The bath ankylosing spondylitis radiology index (BASRI): a new, validated approach to disease assessment.","volume":"41","author":"MacKay","year":"1998","journal-title":"Arthritis Rheum."},{"key":"B14","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1093\/rheumatology\/37.7.760","article-title":"Radiological assessment in psoriatic arthritis.","volume":"37","author":"Rahman","year":"1998","journal-title":"Br J Rheumatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","article-title":"Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score.","volume":"75","author":"Schoels","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-020-00891-x","article-title":"From psoriasis to psoriatic arthritis: insights from imaging on the transition to psoriatic arthritis and implications for arthritis prevention.","volume":"22","author":"Zabotti","year":"2020","journal-title":"Curr Rheumatol Rep."},{"key":"B17","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1136\/ard.62.1.68","article-title":"A polyarticular onset predicts erosive and deforming disease in psoriatic arthritis.","volume":"62","author":"Queiro-Silva","year":"2003","journal-title":"Ann Rheum Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3899\/jrheum.201362","article-title":"Construct validity of the routine assessment of patient index data 3 (RAPID3) in the evaluation of axial spondyloarthritis.","volume":"49","author":"Garc\u00eda-Valle","year":"2022","journal-title":"J Rheumatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force.","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.semarthrit.2021.06.006","article-title":"Axial involvement in psoriatic arthritis: an update for rheumatologists.","volume":"51","author":"Poddubnyy","year":"2021","journal-title":"Semin Arthritis Rheum."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016400","article-title":"Obesity in psoriatic arthritis: comparative prevalence and associated factors.","volume":"98","author":"Queiro","year":"2019","journal-title":"Medicine (Baltimore)."},{"key":"B22","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1136\/annrheumdis-2020-218808","article-title":"Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial.","volume":"80","author":"Baraliakos","year":"2021","journal-title":"Ann Rheum Dis."},{"key":"B23","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update.","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1007\/s10067-019-04519-z","article-title":"Hypertension is associated with increased age at the onset of psoriasis and a higher body mass index in psoriatic disease.","volume":"38","author":"Queiro","year":"2019","journal-title":"Clin Rheumatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41584-019-0256-0","article-title":"Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions.","volume":"15","author":"Ferguson","year":"2019","journal-title":"Nat Rev Rheumatol."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217251","article-title":"Secukinumab efficacy in patients with PsA is not dependent on patients\u2019 body mass index.","volume":"81","author":"Pantano","year":"2022","journal-title":"Ann Rheum Dis."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.679009","article-title":"Multicenter study of secukinumab survival and safety in spondyloarthritis and psoriatic arthritis: secukinumab in cantabria and ASTURias study.","volume":"8","author":"Alonso","year":"2021","journal-title":"Front Med (Lausanne)."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-021-01128-7","article-title":"Interleukin 17A: key player in the pathogenesis of hypertension and a potential therapeutic target.","volume":"23","author":"Davis","year":"2021","journal-title":"Curr Hypertens Rep."},{"key":"B29","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/art.24172","article-title":"Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study.","volume":"61","author":"Wilson","year":"2009","journal-title":"Arthritis Rheum."},{"key":"B30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/00124743-200202000-00006","article-title":"Prevalence and predictors of cervical involvement in psoriatic spondyloarthropathy.","volume":"8","author":"Queiro","year":"2002","journal-title":"J Clin Rheumatol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.891863\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T16:54:05Z","timestamp":1651164845000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.891863\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,28]]},"references-count":30,"alternative-id":["10.3389\/fmed.2022.891863"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.891863","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,28]]},"article-number":"891863"}}